(ARGX) argenx - Ratings and Ratios
Antibody,Autoimmune,Therapy,FcRn,IgG
ARGX EPS (Earnings per Share)
ARGX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 38.2% |
| Value at Risk 5%th | 51.7% |
| Relative Tail Risk | -17.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 46.80 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.535 |
| Beta | 0.476 |
| Beta Downside | 0.592 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.20% |
| Mean DD | 11.09% |
| Median DD | 7.84% |
Description: ARGX argenx September 29, 2025
argenx SE (NASDAQ: ARGX) is a commercial-stage biopharma headquartered in Amsterdam that focuses on antibody-based therapies targeting the neonatal Fc receptor (FcRn) pathway and related immune mechanisms. Its current commercial portfolio includes VYGART™ (efgartigimod) and VYGART HYTRULO™ for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals in the United States, Japan, and the European Union.
The pipeline extends beyond FcRn blockade to a suite of novel biologics: efgartigimod is being evaluated in seronegative/ocular gMG, thyroid eye disease, myositis, Sjögren’s syndrome, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis. Additional candidates include empasiprubart (multifocal motor neuropathy, CIDP, delayed graft function, dermatomyositis), ARGX-119 (MuSK agonist for congenital myasthenic syndromes, ALS, SMA), ARGX-109 (IL-6 inhibition), ARGX-121/ARGX-220 (immune modulation), ARGX-213 (FcRn targeting), and ARGX-118 (anti-Galectin-10). The breadth of indications reflects a strategic bet on high-unmet-need autoimmune and neuro-degenerative markets.
argenx leverages a network of collaborations with major pharma and academic partners, including AbbVie, LEO Pharma, Zai Lab, Chugai, Genmab, and IQVIA. These alliances provide co-development funding, regional commercialization rights, and access to complementary R&D platforms, reducing cash burn while expanding geographic reach into China, Japan, and the United States.
Key financial and market metrics (as of Q2 2024): • Revenue of $210 million, driven primarily by VYGART sales, representing a 45 % YoY increase; • Cash and cash equivalents of $1.2 billion, giving a runway of > 12 months at current burn; • The global FcRn-targeted therapeutics market is projected to grow at a CAGR of ~13 % through 2030, underpinning a favorable macro-trend for argenx’s core technology. • The autoimmune disease market (≈ $150 billion in 2023) continues to expand, with gMG alone expected to reach $6 billion by 2028, supporting long-term demand for the company’s products.
For a deeper quantitative assessment of ARGX’s valuation assumptions and scenario analysis, the ValueRay platform’s analyst models provide a useful starting point.
ARGX Stock Overview
| Market Cap in USD | 55,479m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-05-18 |
| Return 12m vs S&P 500 | 38.3% |
| Analyst Rating | 4.59 of 5 |
ARGX Dividends
Currently no dividends paidARGX Growth Ratios
| CAGR 3y | 35.80% |
| CAGR/Max DD Calmar Ratio | 0.94 |
| CAGR/Mean DD Pain Ratio | 3.23 |
| Current Volume | 430k |
| Average Volume | 321.2k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.62b TTM) > 0 and > 6% of Revenue (6% = 252.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 12.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 113.7% (prev 142.9%; Δ -29.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 479.8m <= Net Income 1.62b (YES >=105%, WARN >=100%) |
| Net Debt (-2.04b) to EBITDA (844.1m) ratio: -2.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.7m) change vs 12m ago 10.53% (target <= -2.0% for YES) |
| Gross Margin 77.07% (prev 90.95%; Δ -13.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.36% (prev 54.91%; Δ 15.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 156.2 (EBITDA TTM 844.1m / Interest Expense TTM 3.96m) >= 6 (WARN >= 3) |
Altman Z'' 3.50
| (A) 0.67 = (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b |
| (B) -0.16 = Retained Earnings (Balance) -1.16b / Total Assets 7.18b |
| (C) 0.10 = EBIT TTM 618.3m / Avg Total Assets 5.99b |
| (D) -0.99 = Book Value of Equity -1.07b / Total Liabilities 1.08b |
| Total Rating: 3.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.99
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 0.92% = 0.46 |
| 3. FCF Margin 11.24% = 2.81 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -2.42 = 2.50 |
| 6. ROIC - WACC (= 1.73)% = 2.16 |
| 7. RoE 32.57% = 2.50 |
| 8. Rev. Trend 48.23% = 3.62 |
| 9. EPS Trend 88.94% = 4.45 |
What is the price of ARGX shares?
Over the past week, the price has changed by +4.39%, over one month by +8.44%, over three months by +37.30% and over the past year by +59.88%.
Is argenx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARGX is around 1077.65 USD . This means that ARGX is currently undervalued and has a potential upside of +15.92% (Margin of Safety).
Is ARGX a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 941.9 | 1.3% |
| Analysts Target Price | 941.9 | 1.3% |
| ValueRay Target Price | 1193.9 | 28.4% |
ARGX Fundamental Data Overview November 15, 2025
P/E Trailing = 38.157
P/E Forward = 36.63
P/S = 15.0623
P/B = 8.9882
P/EG = 1.1886
Beta = -0.111
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 51.59b USD (55.48b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
FCF Yield = 0.92% (FCF TTM 473.5m / Enterprise Value 51.59b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 7.19 (Enterprise Value 51.59b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.64% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 7.79% (E(55.48b)/V(55.52b) * Re(7.79%) + D(43.2m)/V(55.52b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 6.14%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈473.5m ; Y1≈310.9m ; Y5≈142.2m
Fair Price DCF = 45.39 (DCF Value 2.79b / Shares Outstanding 61.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 88.94 | EPS CAGR: 94.61% | SUE: 0.46 | # QB: 0
Revenue Correlation: 48.23 | Revenue CAGR: 61.25% | SUE: 1.33 | # QB: 2
Additional Sources for ARGX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle